Fibroblast growth factor 23, cardiovascular disease, and inflammation

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 7, 2012, Pages 1061-1062

  Stern, Leonard ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 3; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; PARATHYROID HORMONE; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AGE; BLOOD VESSEL CALCIFICATION; BODY MASS; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; EDITORIAL; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; NONHUMAN; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL VASCULAR DISEASE; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; RENOVASCULAR DISEASE; SEX DIFFERENCE; STROKE; SUDDEN DEATH; VITAMIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION;

EID: 84863753497     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05500512     Document Type: Editorial

References (17)

1. Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 13: 73-81, 2004
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
3. Foley RN, Gilbertson DT, Murray T, Collins AJ: Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 365: 1099-1107, 2011
4. Isakova T, Xie H, YangW, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
6. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
7. BarretoDV, BarretoFC, LiabeufS, TemmarM, LemkeHD, TribouilloyC, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550-556, 2010
8. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
9. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 80: 99-102, 2002
10. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68: 237-245, 2005
11. Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif 23: 64-71, 2005
12. DuerMJ, Friscić T, ProudfootD, Reid DG, SchoppetM, Shanahan CM, Skepper JN, Wise ER: Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol 28: 2030-2034, 2008
13. Leaf D, WolfM, Waikar SS, Chase H, Cremers S, Stern L: FGF-23 levels are elevated in patients with AKI and are associated with poor outcomes. ClinJ Am Soc Nephrol, in press
14. Gutié rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, ColleroneG, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
15. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, for the Chronic Renal Insufficiency Cohort: Fibrobast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162, 2012
16. Nordfors L, Lönnqvist F, HeimbürgerO, Danielsson A, SchallingM, Stenvinkel P: Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54: 1267-1275, 1998
17. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N: Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 25: 1711-1723, 2010